Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma

被引：8

作者：

Ishii, Takeaki ^{[1
]}

Kohashi, Kenichi ^{[1
]}

Ootsuka, Hiroshi ^{[1
]}

Iura, Kunio ^{[1
]}

Maekawa, Akira ^{[1
]}

Yamada, Yuichi ^{[1
]}

Bekki, Hirofumi ^{[1
]}

Yoshimoto, Masato ^{[1
]}

Yamamoto, Hidetaka ^{[1
]}

Iwamoto, Yukihide ^{[2
]}

Oda, Yoshinao ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Japan

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2017年 / 213卷 / 06期

关键词：

Molecular targeting therapy; Immunohitochemistry; Leiomyosarcoma; Liposarcoma; Pathology; MALIGNANT FIBROUS HISTIOCYTOMAS; MDM2; P53; DIFFERENTIATION; EXPRESSION; SARCOMAS; PATHWAY;

D O I：

10.1016/j.prp.2017.04.022

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

It is important to distinguish between leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) in the retroperitoneum. The dedifferentiated component of DDLS shows an LMS-like morphology in some cases; thus, detailed evaluation is necessary to achieve an accurate diagnosis. Immunohistochemically, MDM2 and myogenic markers provide clues for the diagnoses. However, immunoreactivity for MDM2 and myogenic markers has not been well studied in retroperitoneal LMS and DDLS. Here, we compared the clinicopathological data of 20 retroperitoneal tumors initially diagnosed as LMS with that of 36 cases of retroperitoneal DDLS and conducted an immunohistochemical study. Four (20%) of the cases initially diagnosed as LMS were immunoreactive for MDM2. Fifteen cases (41.7%) of DDLS showed positive expression of two or more myogenic markers. The patients with LMS with MDM2 overexpression were older than the patients with LMS without MDM2 overexpression (P = 0.0328). LMS with MDM2 overexpression showed a worse prognosis than DDLS (P=0.0408). No significant difference in prognosis was found between LMS without MDM2 overexpression and DDLS with myogenic differentiation. In conclusion, we recommend that systemic MDM2 expression analysis be performed in cases of retroperitoneal sarcoma. Overdependence on the expression of myogenic markers could lead to misdiagnosis in distinguishing LMS from DDLS. (C) 2017 Elsevier GmbH. All rights reserved.

引用

页码：634 / 638

页数：5

共 15 条

[1] Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma [J].